We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Faulty Protein Interaction Disrupts Neuromuscular Junctions and Triggers ALS

By Gerald M. Slutzky, PhD
Posted on 01 Dec 2016
Print article
Image: The neuromuscular junction is the synapse where motor neurons communicate with muscle to initiate voluntary movement. A healthy neuromuscular junction (yellow) is characterized by perfect apposition between the motor neuron (green) and nicotinic acetylcholine receptors on the muscle (red). This synapse is damaged early in ALS, a change believed to contribute the onset and progression of the disease (Photo courtesy of the Virginia Tech Carilion Research Institute).
Image: The neuromuscular junction is the synapse where motor neurons communicate with muscle to initiate voluntary movement. A healthy neuromuscular junction (yellow) is characterized by perfect apposition between the motor neuron (green) and nicotinic acetylcholine receptors on the muscle (red). This synapse is damaged early in ALS, a change believed to contribute the onset and progression of the disease (Photo courtesy of the Virginia Tech Carilion Research Institute).
Humans and mice are protected from developing amyotrophic lateral sclerosis (ALS) by the action of muscle fibers that secrete and concentrate the fibroblast growth factor binding protein 1 (FGFBP1) at neuromuscular junctions.

The FGFBP1 gene encodes a secreted fibroblast growth factor carrier protein, which plays a critical role in cell proliferation, differentiation, and migration by binding to fibroblast growth factors and potentiating their biological effects on target cells.

ALS is a specific disorder that involves the death of neurons. The disease, for which there is no cure, is characterized by stiff muscles, muscle twitching, and gradually worsening weakness due to muscles decreasing in size. Most ALS sufferers die from respiratory failure. The neuromuscular junction (NMJ) is critical for all voluntary movement. Its malformation during development and degeneration during aging or in ALS impairs motor function.

Investigators at the Virginia Tech Carilion Research Institute (Roanoke, VA, USA) reported in the November 14, 2016, online edition of The Journal of Neuroscience that while FGFBP1 expression increased during development, its expression decreased prior to NMJ degeneration during aging and in the SOD1G93A ALS mouse model. FGFBP1 expression was shown to be inhibited by increased accumulation of transforming growth factor-beta1 (TGF-beta1) in skeletal muscles and at their NMJs. When they examined the impact of deleting FGFBP1 on NMJs, the investigators found that in the absence of FGFBP1, NMJs exhibited structural abnormalities in developing and in middle age mice. Deletion of FGFBP1 from SOD1G93A mice also accelerated NMJ degeneration and death.

These findings suggested that targeting the interaction between FGFBP1 and TGF-beta1 signaling could hold promise for slowing age- and disease-related degeneration of NMJs.

"TGF-beta1 is upregulated in ALS and in turn blocks expression of FGFBP1, which is released by muscle fibers to preserve the integrity of the neuromuscular junction," said senior author Dr. Gregorio Valdez, assistant professor of biological sciences at the Virginia Tech Carilion Research Institute. "The body is trying to help itself by generating more TGF-beta1. Unfortunately, TGF-beta1 accumulates at the synapse where it blocks expression of FGFBP1, accelerating degeneration of the neuromuscular junction. Our findings suggest that targeting these molecules may allow these important synapses to stay in place, and slow the progression of ALS."

Related Links:
Virginia Tech Carilion Research Institute

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.